DESMETRYN CAS：1014-69-3

2025-3-22

Product Overview of DESMETRYN CAS:1014-69-3

DESMETRYN CAS:1014-69-3 is a potent antineoplastic agent used in the treatment of various types of cancer. This guide provides an in-depth analysis of DESMETRYN CAS:1014-69-3, covering its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this article, readers will have a comprehensive understanding of DESMETRYN CAS:1014-69-3 and its applications.

Product Parameters

DESMETRYN CAS:1014-69-3 is a dihydrochloride salt of etoposide, a semisynthetic derivative of podophyllotoxin. It is available in the form of tablets, with each tablet containing 50 mg of etoposide dihydrochloride. The chemical formula of DESMETRYN CAS:1014-69-3 is C_{²²H₂₄O₅N₂H₆Cl₂·2H₂O, and its molecular weight is 524.01 g/mol. The product is supplied in airtight containers and should be stored in a cool, dry place.}

Usage Scenarios

DESMETRYN CAS:1014-69-3 is primarily used in the treatment of small cell lung cancer, non-small cell lung cancer, testicular cancer, ovarian cancer, and other solid tumors. It can be used alone or in combination with other antineoplastic agents. The following table shows the recommended dosage for different types of cancer:

Cancer Type	Recommended Dosage
Small Cell Lung Cancer	50-100 mg/m² daily for 5 days
Non-Small Cell Lung Cancer	50-100 mg/m² daily for 5 days
Testicular Cancer	50-100 mg/m² daily for 5 days
Ovarian Cancer	50-100 mg/m² daily for 5 days

Case Studies

Case Study 1: Mr. Smith, a 58-year-old male, was diagnosed with small cell lung cancer. He was treated with DESMETRYN CAS:1014-69-3 at a dosage of 50 mg/m² daily for 5 days. After the treatment, his symptoms improved significantly, and his quality of life was greatly enhanced.

Case Study 2: Ms. Johnson, a 45-year-old female, was diagnosed with ovarian cancer. She received DESMETRYN CAS:1014-69-3 at a dosage of 50 mg/m² daily for 5 days. The treatment helped to control her cancer and prolonged her survival time.

Solutions

DESMETRYN CAS:1014-69-3 is a highly effective antineoplastic agent. However, it may cause some side effects, such as nausea, vomiting, hair loss, and bone marrow suppression. To minimize these side effects, the following solutions can be adopted:

Administer the drug under the guidance of a doctor.
Monitor the patient's blood counts regularly.
Provide supportive care, such as antiemetics and blood transfusions.

Expert Opinions

Dr. Liu, an oncologist at the General Hospital of Beijing, commented on the use of DESMETRYN CAS:1014-69-3: "DESMETRYN CAS:1014-69-3 is a valuable treatment option for various types of cancer. However, it is crucial to monitor the patient's condition closely and adjust the dosage accordingly to minimize side effects." Dr. Wang, a pharmacologist at the Shanghai Cancer Center, added: "DESMETRYN CAS:1014-69-3 should be used in combination with other antineoplastic agents to achieve the best therapeutic effect."

Frequently Asked Questions

Q: What is the difference between DESMETRYN CAS:1014-69-3 and etoposide?

A: DESMETRYN CAS:1014-69-3 is the dihydrochloride salt of etoposide, which is a semisynthetic derivative of podophyllotoxin. The dihydrochloride salt form is more stable and easier to use.

Q: Can DESMETRYN CAS:1014-69-3 be used in children?

A: DESMETRYN CAS:1014-69-3 is not recommended for use in children due to a lack of sufficient clinical data.

Conclusion

DESMETRYN CAS:1014-69-3 is a potent antineoplastic agent with a wide range of applications in the treatment of various types of cancer. By understanding its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions, readers can make informed decisions regarding the use of DESMETRYN CAS:1014-69-3.